Профилактика и лечение дегенерации макулы и заднего полюса глаза

Н. В. Коновалова; Н. И. Нарицына; А. Я. Новик; А. В. Рыбалко

doi:10.31288/oftalmolzh201324850

Prevention and treatment of macular degeneration and eye posterior pole

Authors

N. V. Konovalova State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)
N. I. Naritsyna State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)
A. Ya. Novik State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)
A. V. Rybalko State Institution The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine, Odessa, (Ukraine)

DOI:

https://doi.org/10.31288/oftalmolzh201324850

Keywords:

macular degeneration and posterior pole, Ocuvite Complete

Abstract

The use of the drug Ocuvite Complete 1 capsule two times for four months helped to stabilize visual function in 83 % of patients and improve visual acuity in 26.3 % of ofpatients. Ocuvite complete serves to prevent the development of degeneration macula and posterior poles and contributes to the stabilization of visual function.

References

1.Кански Дж. Дж. Заболевания глазного дна / Дж.Дж. Кански // Под ред. С. Э. Аветисова. - М., 2008. - 3153 с.

2.Морозов В. И. Фармакотерапия глазных болезней / В. И. Морозов, А. А. Яковлев // М.: Медицина. - 2004. - 512 с.

3.Brown D. M. Ranibizumab versus verteporfm for neovas-cular age-related macular degeneration / D. M. Brown, P. K. Kaiser, М. Michels // N. Engl. J. Med. - 2006. - Vol. 5. - P. 1432- 1444 https://doi.org/10.1056/NEJMoa062655

4.Carneiro A. M. Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab/А. М. Carneiro // Ophthalmologica. - 2011. - Feb.18. - P.211-225 https://doi.org/10.1159/000323943

5.Gaudreault J. Preclinical pharmacokinetics of Ranibizumab (rhuRabV2) after a single intravitrical administration/ J. Gaudreault, D. Fei, J. Rusit // Invest. Ophthalmol. - 2005. - Vol. - 46. - P. 726- 733. https://doi.org/10.1167/iovs.04-0601

6.Regillo C. D. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1/ C. D. Regillo, D. M. Brown, P. Abraham // Am. J. Ophthalmol. - 2008. - Vol. 145. - P. 239- 248. https://doi.org/10.1016/j.ajo.2007.10.004

7.Towler H. Age related macular degeneration // H. Towler, S. Lightman / British Medical Journal Ophthalmology. - 1996. - V.312. - P.89- 92. https://doi.org/10.1136/bmj.312.7035.889

Downloads

UKR (Ukrainian)

Published

2013-04-28

Issue

No. 2 (2013): Journal of Ophthalmology (Ukraine)

Section

Clinical Ophthalmology

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.

COPYRIGHT NOTICE

Authors who publish in this journal agree to the following terms:

Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
The copyright commencement date complies the publication date of the issue, where the article is included in.

DEPOSIT POLICY

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
Archiving the pre-print (pre-refereeing manuscript version) not allowed.